Drug Trial Radar · NCT03399370
Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
Last checked: Nov 19, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,561
Actual
Start
Dec 21, 2017
Primary completion
Sep 10, 2019
Study completion Sep 17, 2019
Sponsor
- Lead sponsor
- The Medicines CompanyIndustry
- Sponsor type
- Industry
- First posted
- Jan 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s). The study will be a multicenter study in the United States.
Conditions
- ASCVD
- Elevated Cholesterol
Interventions
Inclisiran SodiumDrug
Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
PlaceboDrug
Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change in LDL-C From Baseline to Day 510Time frame: Baseline, Day 510
- Time-adjusted Percentage Change in LDL-C Levels From Baseline After Day 90 and up to Day 540Time frame: Baseline, Day 90 to Day 540
Locations
145 sites in 1 country. Site status is shown where the registry gives one.
Research Site 10001-015
Birmingham, Alabama
Research Site 10001-138
Foley, Alabama
Research Site 10001-113
Huntsville, Alabama
Research Site 10001-058
Mobile, Alabama
Research Site 10001-037
Montgomery, Alabama
Research Site 10001-076
Saraland, Alabama
Research Site 10001-013
Chandler, Arizona
Research Site 10001-077
Mesa, Arizona
Research Site 10001-136
Phoenix, Arizona
Research Site 10001-051
Surprise, Arizona
Research Site 10001-019
Tucson, Arizona
Research Site 10001-004
Tucson, Arizona
Research Site 10001-132
Tucson, Arizona
Research Site 10001-073
Beverly Hills, California
Research Site 10001-050
Canoga Park, California
Research Site 10001-011
Carlsbad, California
Research Site 10001-065
El Cajon, California
Research Site 10001-150
Los Angeles, California
Research Site 10001-043
Northridge, California
Research Site 10001-022
Northridge, California
Research Site 10001-033
Sacramento, California
Research Site 10001-105
San Ramon, California
Research Site 10001-008
Santa Rosa, California
Research Site 10001-153
Spring Valley, California
Research Site 10001-044
Torrance, California
Research Site 10001-047
Boca Raton, Florida
Research Site 10001-084
Clearwater, Florida
Research Site 10001-155
Clearwater, Florida
Research Site 10001-099
Clearwater, Florida
Research Site 10001-127
Daytona Beach, Florida
Research Site 10001-119
Fleming Island, Florida
Research Site 10001-070
Fort Lauderdale, Florida
Research Site 10001-067
Hialeah, Florida
Research Site 10001-139
Jacksonville, Florida
Research Site 10001-039
Jacksonville, Florida
Research Site 10001-098
Jacksonville, Florida
Research Site 10001-081
Miami, Florida
Research Site 10001-140
Miami, Florida
Research Site 10001-142
Miami, Florida
Research Site 10001-030
Miami, Florida
Showing 40 of 145 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.